Max Medikit Labs Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 11 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth -19.71%
- Profit Growth -71.13%
- Ebitda 199.21%
- Net Worth -4.02%
- Total Assets 121.68%
About Max Medikit Labs
Max Medikit Labs Private Limited (MMLPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 March 2014 and has a history of Ten years and 11 months. Its registered office is in Delhi, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ravi Shanker and Daya Shankar serve as directors at the Company.
Company Details
-
Location
Delhi, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U33110DL2014PTC265672
-
Company No.
265672
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Mar 2014
-
Date of AGM
30 Sep 2022
-
Date of Balance Sheet
31 Mar 2022
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
What products or services does Max Medikit Labs Private Limited offer?
Max Medikit Labs Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Nutritional Supplements.
Who are the key members and board of directors at Max Medikit Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ravi Shanker
|
Director | 01-Mar-2014 | Current |
|
Daya Shankar
|
Director | 01-Mar-2014 | Current |
Financial Performance of Max Medikit Labs.
Max Medikit Labs Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 19.71% decrease. The company also saw a substantial fall in profitability, with a 71.13% decrease in profit. The company's net worth dipped by a decrease of 4.02%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Max Medikit Labs?
In 2019, Max Medikit Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Max Medikit Labs?
Unlock and access historical data on people associated with Max Medikit Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Max Medikit Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Max Medikit Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.